Novartis Wins EU Approval for Lucentis for Myopic Choroidal Neovascularization

NovartisNovartis International AG has informed that Lucentis has got European Commission approval for treatment of patients suffering from choroidal neovascularization. Swiss pharmaceutical giant has registered sales of $2.4 billion during year 2012 for Lucentis, launched by the company in 2006.

Lucentis has already been approved in European Union for age-related macular degeneration and visual impairment due to macular edema secondary to vien occlusion in retina. Novartis informed that single injection of Lucentis has proved helpful in 70% of the patients and they achieved good results in rapid visual gains.

Novartis performed study under name RADIANCE for patients suffering from myopic choroidal neovascularization. The study subjects were feeling better effects of the treatment with 2 injections in 60% of the cases. The patients didn't require any additional injections after six months.

Novartis competes with Regeneron's Eylea in the same segment. Eylea has been gaining market share in Europe and United States, market dominated by Lucentis since its launch in 2006 in United States. In United States, the drug is sold by Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG.